Taysha Gene Therapies Inc. (TSHA): Price and Financial Metrics
TSHA Price/Volume Stats
| Current price | $2.01 | 52-week high | $4.32 |
| Prev. close | $2.12 | 52-week low | $1.19 |
| Day low | $1.96 | Volume | 8,624,100 |
| Day high | $2.12 | Avg. volume | 2,675,774 |
| 50-day MA | $1.97 | Dividend yield | N/A |
| 200-day MA | $2.41 | Market Cap | 411.94M |
TSHA Stock Price Chart Interactive Chart >
Taysha Gene Therapies Inc. (TSHA) Company Bio
Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.
TSHA Price Returns
| 1-mo | 1.01% |
| 3-mo | -8.64% |
| 6-mo | -37.96% |
| 1-year | 9.24% |
| 3-year | -82.94% |
| 5-year | N/A |
| YTD | 13.56% |
| 2023 | -21.68% |
| 2022 | -80.60% |
| 2021 | -56.10% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...